INTRODUCTION
The abilities of skeleton to articulate in various opposing directions and to serve as levers for muscle action are fundamental to mobility and locomotion in vertebrates. Skeleton also plays important roles in maintaining blood calcium levels, supporting haematopoiesis, and housing the brain and the spinal cord [1] . Consequently, skeletal defects often incur considerable morbidity. Conventional medical strategies have barely cured irreversible tissue defects, focusing on the removal of causes of diseases. For the repair of tissue defects, they mostly rely on natural healing abilities of tissues, helping the abilities to be exerted efficiently. In bone and cartilage, irreversible tissue defects are caused by aging, trauma, disease, tumor, and developmental abnormalities.
Bone grafts and prosthetic implant devices have been used to repair irreversible bone defects. Autograft is superior to the other techniques in function and engraftment, because it is a bone tissue derived from the same individual containing live cells and growth factors. Autograft is thought to have both the ability to facilitate bone regeneration (osteoconductivity) and the ability to actively induce bone regeneration (osteoinductivity) and is speedily fused and integrated to the bone of the implantation site. However, the donor site morbidity often occurs, because autogaft requires highlyinvasive bone collection surgery from healthy sites [2] . Although allograft is free from the invasiveness and less restricted in quantity, it runs a biological risk of contamination by pathogens as well as an ethical risk [3] . In allograft, no live cells are present, and growth factors are inactivated to some extent, since it is usually heat-treated and kept frozen in order to reduce immunological reactions. Therefore, its osteoconductivity and osteoinductivity are inferior to those of autograft.
Several strategies for the treatment of cartilage defects have been reported: autograft of periosteum and perichondrium, cartilage transplantation, and mechanical penetration of subchondral bones for the bone marrow entry into the defect site. However, they failed to provide reproducible results or complete repair of the defects [4] .
In addition, common to the procedures for both bone and cartilage defects, physicians have to manually carve grafts to fit them to deformities during surgery, which is often time-consuming and laborious and associated with low precision [5] . Thus, grafts have shortcomings concerning both quantity (availability of suitable graft material) and quality (donor site troubles, graft rejection and disease transmission). Prosthetic implants overcome some problems associated with grafts, but have shortcomings concerning biocompatibility, function, and longevity.
Tissue engineering of bone and cartilage has drawn attention as an approach which provides solutions to such problems. Back in 1993, Langer and Vacanti [6] proposed three components for the creation of new tissues: cell sources, tissue-inducing factors (signaling factors), and scaffolds. To bring tissue engineering into reality, it is crucial to justify and optimize the use of each component as well as to sufficiently advance and combine the three components [7] . This paper aims to review current progress on tissue engineering of bone and cartilage, focusing on important translational studies as well as preclinical studies. We also discuss major obstacles and future perspectives in this field. According to the three components for tissue engineering, the review is composed of the following sections: 
Signaling factors
Substantial evidences have been accumulated in the past few years to understand major osteogenic signaling molecules and genes: bone morphogenetic proteins (BMPs) [8] , Hedgehogs (Hh) [9, 10] , runt-related transcription factor 2 (Runx2) [11, 12] , Wnts [13] , fibroblast growth factors (FGFs) [14] (ref) and insulin-like growth factors (IGFs) [15] . Among them, BMPs have been most extensively studied in clinical settings. Efficacy of recombinant human BMP-2 (rhBMP-2) and rhBMP-7 in fracture repair of tibia and spine fusion has been shown by several clinical trials [16] . However, a large amount of BMP is required for the treatments, and BMP-containing devices often fail, raising concerns over costs and safety [17] [18] [19] .
The reasons may be related to a lack of delivery systems which enables the release of BMPs in a controlled-and sustained-manner, short biological half-life of BMPs, and difficulties to mimic the biological condition [20] . The efficacy of FGF-2 on bone repair was also examined in clinical settings as well as in preclinical studies. Aiming at the clinical application of autologous chondrocytes to cartilage regeneration, the combination of growth factors was optimized to expand human chondrocytes and to re-differentiate dedifferentiated chondrocyes in culture [49, 50] . The combination of FGF-2 with insulin or IGF-I was suggested to be useful for promotion of chondrocyte proliferation [49] . Also, the combination of BMP-2, insulin, and triiodothyronine was found to be the most effective for the re-differentiation of the de-differentiated cells after repeated passages [50] .
Cells
In bone and cartilage tissue engineering, autologous cell trans- [51, 52] . The cells have been reported to have abilities to differentiate into nerve cells [53] and hepatocytes [54] as well as cells derived from mesenchyme such as osteoblasts, chondrocytes, adipocytes, and muscle cells [55, 56] . When infused into children with osteogenesis imperfecta, bone marrow MSCs induced new lamellar bone formation and an increase in the total body mineral content with the increased number of osteoblasts [57, 58] . Quarto et al. [59] described treatment of patients with large bone defects with autologous MSCs in combination with porous ceramic scaffolds. In the treatment of non-or delayed union, clinical studies have been performed to examine the efficacy of bone marrow cells [16] .
As for the use of autologous MSCs in cartilage defects, Wakitani et al. and Kuroda et al. [60] [61] [62] [63] reported cartilage repair in human by the implantation of autologous bone marrow MSC-containing collagen gels into knees. To examine the possibility that MSCs might form tumors during long-term follow-up, they further investigated tumor development and infections in 41 patients who had undergone autologous bone marrow implantation for cartilage repair. In the follow-up ranging from 5 to 137 months (11 years and 5 months), they found that none of the patients had infections or tumors [64] .
Synovium has also drawn attention as another source of MSCs. A couple of studies have shown that MSCs isolated from synovium (synovial MSCs) show higher chondrogenic capacity than MSCs isolated from other tissues. Sakaguchi et al. [65] found in vitro that human synovial MSCs had higher capacity to differentiate into chondrocytes than MSCs derived from any other tissues including bone marrow, periosteum, muscle, and adipose tissue. Synovial MSCs induced cartilage repair more potently than muscle-or adipose tissue-derived ones in a rat cartilage defect model [66] . Moreover, synovial MSCs were reported to expand more than bone marrow MSCs with autologous human serum in vitro [67] . These data suggest that synovial MSCs are a more potent cell source for cartilage repair than bone marrow MSCs. However, isolating MSC from synovium is more difficult than that from bone marrow, which is a reason why bone marrow MSCs have been used more widely [68] .
MSCs still have technical limitations both in quantity and differentiation capacity. More than 10 9 cells are supposed to be required for the treatment of clinical bone defects [69] . However, only 10 3 to 10 6 cells can be isolated from 10 mL of bone marrow fluid or adipose tissue [69, 70] , and it is difficult to expand MSCs by several rounds of passages without affecting their differentiation capacity [71] .
On the other hand, embryonic stem cells (ESCs) proliferate practically indefinitely and possess pluripotency (an ability to give rise to all cell types of embryo) [72] . The cells, isolated from the inner cell mass of blastcysts, were initially established from mouse embryo in 1980s [73, 74] and later in 1998 from human [75] . In vitro studies have shown that human and mouse ES cells can differentiate into osteoblatic cells under certain conditions. In a basic differentiation protocol [76] , embryoid bodies (EBs) derived from ESCs are cultured in an osteogenic medium containing dexamethazone, beta glycerophosphate, and ascorbic acid, which was originally developed for osteogenic induction of bone marrow MSCs and primary osteoblasts [77] . The protocol has been modified with the addition of BMP-2 [78] , BMP-4 [79] , compactin [78] , vitamin D3 [80] , or Leucine-rich amelogenin peptide [81] . Compared with substantial evidences for in vitro osteogenic differentiation of ESCs, their capacities of in vivo bone formation appeared to be poor [82] . Jukes et al.
[ 83] reported in 2008 that they successfully achieved bone regeneration in rat bone defect model using mouse ESCs by mimicking the process of endochondral ossification, where cartilage first formed and then it was replaced by bone tissues. Utilizing abundant autologous adult cells such as skin fibroblasts may overcome problems associated with the use of stem cells. We and others have shown that skin fibroblasts can be a cell source for bone and cartilage regeneration. Hirata et al. [95] and Krebsbach et al. [96] described in vivo bone regeneration using dermal fibroblasts that were infected with adenoviruses expressing BMP-7 and BMP-2, respectively. We reported the efficacy of optimized osteogenic signal on in vivo bone regeneration using mouse dermal fibroblasts
[27] and the induction of chondrocyte markers in human skin fibroblasts in vitro by overexpressing the SOX trio [48] . Because the fibroblast-derived chondrocytes appeared to form fibrocartilage rather than hyaline cartilage, Hiramatsu et al. [97] hypothesized that type 
Scaffolds for bone tissue engineering
In bone tissue engineering, three biomaterials (metals, ceramics, and polymers) have been widely used. Titanium, a traditional inert biomaterial for implants, is characterized by a minimal immune response, which is the biggest advantage of this material. Some studies have shown that titanium fiber meshes or titanium with Zinccontaining hydroxyapatite enhance the osteogenic activity or the proliferation of seeded cells [98] [99] [100] . However, Tortelli and Cancedda [101] pointed out that the difficulty in performing histological analyses was a serious drawback in further investigating the biological activity of this material.
Hydroxyapatite-and beta-tricalcium phosphate (beta-TCP)-based scaffolds are widely used, and several different bioceramics have been developed in order to improve their properties [102] [103] [104] [105] . In particular, calcium phosphates are the most popular materials for artificial bones [106, 107] . Their biocompatibility and biosafety are,
in a sense, already tested in the living body, since approximately 70% of bone of our body is made of the calcium phosphates [108] .
The calcium phosphates are known to be naturally osteoconduc- We also developed a novel tetrapod-shape granular artificial bone using micro-particles of alpha-TCP by injection molding, (manuscript in preparation). When stuffed in a space, the artificial bones were proven to form more effective intergranular pores for cell and vascular invasion because of their homogeneous shape and size.
The artificial bones usually require post-fabrication sintering process to increase their mechanical properties, which causes contraction in size and often decreases biodegradability, as well as shape adjustment during surgery [110] [111] [112] [113] . Therefore, there is a need for novel artificial bones that have better shape compatibility to deformities, appropriate mechanical strength without the post-fabrication sintering, and biodegradability. By controlling the three dimentional (3D) shape of the scaffolds, we have developed artificial bones with good dimensional compatibility, which results in reduction in the operation time, invasiveness, and speedy union with the host bone tissues [114] [115] [116] . Oka et al. [117] also reported the use of customized hydroxyapatite implants which had preoperatively cut into a shape, based on a computer simulation with 3D-computed tomography (CT) data, in opening wedge osteotomy.
Biodegradable synthetic polymers applied to bone tissue engineering include poly (lactic acid) (PLA), poly (glycolic acid) (PGA), poly (-caprolactone), and poly (lactic-coglycolide) (PLGA) copolymers [118] [119] [120] [121] [122] [123] [124] [125] [126] . Cellular adhesion to PLGA is significantly higher than on PLA surfaces, and PLGA scaffolds were shown to induce osteoblast proliferation and differentiation. PLGA supported proliferation and differentiation of osteoblasts, as shown by high alkaline phosphatase activity and deposition of a mineralized matrix [127, 128] . PLGA has been also utilized for encapsulation and release of several growth factors including TGF-β, BMPs, IGFs, vascular endothelial growth factor, and nerve growth factor. Several studies have tested variable sized PLGA microspheres with growth factors and subsequent embedding of them in other polymer matrices with variable degradation rates [129] . Nie and Wang [130] reported the delivery of plasmids expressing BMP-2 using PLGA/Hydroxyapatite composite scaffolds. Takaoka and their colleagues studied PLA derivatives and their composites with other materials as a carrier of rhBMP-2 [131] [132] [133] [134] . They combined a block co-polymer of PLA-p-dioxanone-poly (ethylenglycol) (PEG) and beta-TCP (PLA/ PEG/beta-TCP) [135] . The efficacy of the rhBMP-2-loaded PLA/ PEG/beta-TCP in bone repair has been shown by various animal models relevant to clinical situations [136] [137] [138] [139] . Although Poly (ε-caprolactone) carries biocompatibility and processability, it is less suitable for long term applications because of its high hydrophobicity and low degradability in vivo [140] .
Among natural polymers, bovine type I collagen has been used Given that collagens are dominant and important matrix in bone tissues, it makes sense that the scaffold has biocompatibility as well as the activity to facilitate osteogenesis or cell proliferation. However, two major concerns, disease transmission from other species and its poor mechanical property, remain to be solved.
Scaffolds for cartilage tissue engineering
Scaffolds for cartilage tissue engineering are classified into three groups: polysaccharide-based natural, protein-based natural, and synthetic biomaterials. Polysaccharide-based materials include alginate, chitosan, cellurose, and hyaluronic acid [4] . Hyalograft C, the combination of a hyaluronic-acid-based matrix HYAFF-11 (Fidia Advanced Biopolymers, Abano Terme, Italy), and autologous chondrocytes, is used in clinical settings [142] .
Among protein-based materials, bilayer collagen type I and III membranes are clinically available for autologous chondrocyte implantation (ACI): MACI (Matrix-induced ACI; Verigen, Leverkusen, Germany), Maix (Matricel, Hezoenrath, Germany) and Chondrogide (Geistlich Biomaterials, Wolhusen, Switzerland) [4] . Atelocollagen (Koken Co., Ltd., Tokyo, Japan) is a type I collagen gel, from which telopeptide causing antigenecity is removed. The material has an advantage in generating 3D structure of implant. Ochi et al. [143, 144] have applied the aterocollagen as a carrier of chondrocytes in ACI. However, when implanted, the ateloacollagen-cell composites should be covered with periosteum not to be detached from implantation sites [145] . In addition, fibrin glue (Tissucol, BAXTER, Vienna, Austria) was used for cartilage repair, and its 1-year clinical results were reported by Visna et al. [146] .
PEG is used to create synthetic-based hydrogels in cartilage tissue http://www.enm-kes.org engineering. Chondrocytes remained viable and synthesized cartilage-specific extracellular matrix, even when they were encapsulated in a PEG hydrogel under a compressive modulus (i.e., 260-900 kPa) similar to that of human cartilage (i.e., 790 ± 360 kPa) [147, 148] . Bio-Seed-C (BioTissue Technologies, Freiburg, Germany)
is a clinically-available synthetic material, in which a porous 3D scaffold consisting of PGA, PLA, and polydioxanone is combined with autologous chondrocytes embedded in fibrin gel. Bio-Seed1-C (BioTissue Technologies) induced the formation of hyaline cartilage and a significant clinical improvement of joint function [149] .
Conclusions and future perspectives
Since human multipotent MSCs were isolated, expanded, and characterized in the late 1990s [56] , In bone tissue engineering, for example, it appears possible to repair some bone defects without cell transplantation by inducing host tissues' regeneration abilities with scaffolds alone or the combination of scaffolds and signaling factors (Fig. 1) . Therefore, it seems advisable to start by considering simple strategies before resorting to complicated strategies using cells. We believe that in tissue engineering, using stem cells is not an end, but a means that has to be justified and optimized for individual cases. To advance this field more steadily and rapidly than ever before, we should attempt to build multi-disciplinary collaboration, which will open a new avenue for the realization of tissue-engineering-based therapies. 
